| Pharmacy Times | All Publications

Preventing Rasagiline Drug Interactions

ByJohn R. Horn, PharmD, FCCP,Philip D. Hansten, PharmD

January 1st 2007

nacds SPEAKS OUT: Specialty Pharmaceuticals on the Rise

ByRobert W. Hannan

January 1st 2007

Strategies for Coping with Alzheimer's Disease

ByJena L. Ivey, PharmD, BCPS

January 1st 2007

Captive at the Counter: When Robbers Take Hostages—Part 1

ByCmdr John Burke

January 1st 2007

A Third Category? Medicines Go Behind the Counter

ByWendy K. Bodine, Assistant Editor

January 1st 2007

Avoiding Common Dispensing Errors

ByEileen Koutnik-Fotopoulos, Staff Writer

January 1st 2007

Pharm School Receives Grant to Help with Part D

ByWendy K. Bodine, Assistant Editor

January 1st 2007

compounding HOTLINE

ByMartin A Erickson III, RPh

January 1st 2007

The Pharmacist's Role in the Management of Alzheimer's Disease

ByYvette C. Terrie, BSPharm, RPh

January 1st 2007

A Challenging Path to a PharmD Degree

ByIris Rosendahl

January 1st 2007

Pharmacy Times Contributor Publishes New Book

January 1st 2007

Share Your Pharmacy Pet Peeves

January 1st 2007

case STUDIES

ByLauren S. Schlesselman, PharmD,Christopher Konecny

January 1st 2007

pharmacy TECHNOLOGY news

January 1st 2007

DRUG-ELUTING STENTS MAY POSE CLOTTING RISK

ByAnna D. Garrett, PharmD, BCPS, CPP

January 1st 2007

generic times: product profiles

ByJim Middleton, BS, RPh

January 1st 2007

Future Leaders

ByJames C. McAllister III, MS, FASHP,Pharmacy Times Editor, Health-Systems Pharmacy Section

January 1st 2007

CLOTS UNLIKELY TO MIGRATE AFTER 5 TO10 DAYS

ByAnna D. Garrett, PharmD, BCPS, CPP

January 1st 2007

GENERIC WARFARIN A SAFE SUBSTITUTE

ByAnna D. Garrett, PharmD, BCPS, CPP

January 1st 2007

TIPS FOR MANAGING NOSEBLEEDS

ByAnna D. Garrett, PharmD, BCPS, CPP

January 1st 2007

LOW GENERIC DRUG COPAYS INCREASE COMPLIANCE

January 1st 2007

Considerations for Generic Drug Use in the Elderly

ByDavid J. Caldwell, PharmD,Kelly Jaubert, PharmD,Michelle Zagar, MEd, PharmD,Justin Sherman, MCS, PharmD

January 1st 2007

FIRMS PROTEST CANADIAN PATENT RULES

January 1st 2007

ASTRAZENECA AND PAR SIGN AUTHORIZED GENERIC DEAL

January 1st 2007

GENERIC LEADERS OUTLINE PROSPECTS FOR NEW CONGRESS

January 1st 2007

OKLAHOMA PHARMACISTS WILL FACE HIGHER GENERICS COSTS

January 1st 2007

FDA APPROVES FIRST GENERIC ONDANSETRON

January 1st 2007

EU GENERIC FIRMS RESPOND TO "BIOSIMILAR" CRITICISMS

January 1st 2007

US GENERIC INDUSTRY OPPOSES CHANGES FOR BIOMEDS

January 1st 2007

Treating the Common Cold

ByJulie L. Olenak, PharmD

January 1st 2007

Preventing Rasagiline Drug Interactions

nacds SPEAKS OUT: Specialty Pharmaceuticals on the Rise

Strategies for Coping with Alzheimer's Disease

Captive at the Counter: When Robbers Take Hostages—Part 1

A Third Category? Medicines Go Behind the Counter

Avoiding Common Dispensing Errors

Pharm School Receives Grant to Help with Part D

compounding HOTLINE

The Pharmacist's Role in the Management of Alzheimer's Disease

A Challenging Path to a PharmD Degree

Pharmacy Times Contributor Publishes New Book

Share Your Pharmacy Pet Peeves

case STUDIES

pharmacy TECHNOLOGY news

DRUG-ELUTING STENTS MAY POSE CLOTTING RISK

generic times: product profiles

Future Leaders

CLOTS UNLIKELY TO MIGRATE AFTER 5 TO10 DAYS

GENERIC WARFARIN A SAFE SUBSTITUTE

TIPS FOR MANAGING NOSEBLEEDS

LOW GENERIC DRUG COPAYS INCREASE COMPLIANCE

Considerations for Generic Drug Use in the Elderly

FIRMS PROTEST CANADIAN PATENT RULES

ASTRAZENECA AND PAR SIGN AUTHORIZED GENERIC DEAL

GENERIC LEADERS OUTLINE PROSPECTS FOR NEW CONGRESS

OKLAHOMA PHARMACISTS WILL FACE HIGHER GENERICS COSTS

FDA APPROVES FIRST GENERIC ONDANSETRON

EU GENERIC FIRMS RESPOND TO "BIOSIMILAR" CRITICISMS

US GENERIC INDUSTRY OPPOSES CHANGES FOR BIOMEDS

Treating the Common Cold

Trending on Pharmacy Times

Higher-Dose Semaglutide Achieves Significant Weight Reduction in Adults with Obesity

Ethical Considerations of Artificial Intelligence Use Abound

Looking Forward to 2026: Do More With Less

The Average Health Insurance Premium Now Costs $27k Per Year for a Family

Prevention for Protection: The Evolution of Heart Failure Management